Program
QLM3003
A development code. Also written as “1.5% QLM3003 ointment”, “2% QLM3003 ointment” and “1.5% QLM3003”.
Its studies are mostly in Dermatitis, Atopic, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 31 open or running | phase 3since Mar 11, 2025 | Jun 22, 2023 | Mar 2027phase 3 · NCT06880276 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 22, 2023First study: phase 1 study in Dermatitis, AtopicFirst studyNCT05932888 · 40 enrolled · China
- Sep 21, 2023Phase 2 study in Dermatitis, AtopicNCT06058000 · 120 enrolled · China
- Mar 11, 2025Phase 3 study in Dermatitis, AtopicNCT06880276 · 360 planned · China
Ahead
- Mar 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT06880276
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06880276Dermatitis, Atopic · China | 3 | Recruiting | Mar 2027 | 360 |
| NCT06058000Dermatitis, Atopic · China | 2 | Completed | Sep 2, 2024 | 120 |
| NCT05932888Dermatitis, Atopic · China | 1 | Completed | Aug 5, 2023 | 40 |
How it is read
Names in the registry
- “1.5% QLM3003 ointment”, 1 entry
- “2% QLM3003 ointment”, 1 entry
- “1.5% QLM3003”, 1 entry
- “2% QLM3003”, 1 entry
- “QLM3003”, 1 entry
Codes read as this program: QLM3003.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.